Comparative Pharmacology
Head-to-head clinical analysis: FERIDEX I V versus GASTROGRAFIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FERIDEX I V versus GASTROGRAFIN.
FERIDEX I.V. vs GASTROGRAFIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FERIDEX I.V. (ferumoxytol) is an iron oxide nanoparticle coated with a carbohydrate shell. After intravenous administration, ferumoxytol is taken up by macrophages of the reticuloendothelial system, releasing iron into the intracellular iron pool. Iron is transported by transferrin to erythroid precursor cells for hemoglobin synthesis, thereby replenishing iron stores.
Gastrografin is a water-soluble iodinated contrast agent that increases the radiodensity of the gastrointestinal tract, allowing visualization on X-ray. It acts by absorbing X-rays due to its high iodine content.
15 mg/kg intravenous infusion over 4 hours, maximum single dose 1200 mg, repeat after 72 hours if ferritin <100 ng/mL and transferrin saturation <20%.
Oral or rectal: 50-100 mL of a 1:1 dilution with water (or full strength as needed) for CT or fluoroscopic studies. Typically single dose.
None Documented
None Documented
Terminal elimination half-life (t½) of ferric carboxymaltose is approximately 7-12 hours (mean ~9 hours) in iron-deficient patients. Clinical context: The iron is rapidly delivered to the reticuloendothelial system for processing; reticulocyte response is seen within 1-2 weeks. The half-life reflects clearance of the complex from plasma, not iron turnover.
Terminal elimination half-life: 1-2 hours (for absorbed diatrizoate); prolongation in renal impairment (up to 20 hours in anuria).
Primarily eliminated via hepatobiliary and fecal routes as intact complex; renal excretion is minimal (<1%) for iron, but ferric carboxymaltose complex is not dialyzable. In patients with iron deficiency, ~50-60% of administered iron is incorporated into hemoglobin and red blood cells within 2-4 weeks; the remainder is stored as ferritin and hemosiderin. The carboxymaltose moiety is partially metabolized and excreted via urine and feces.
Renal: 80-90% (glomerular filtration, unchanged); Biliary/Fecal: <5% (minor biliary excretion of absorbed fraction).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent